Endo Launches First Generic Version of Amgen’s RAVICTI, Expanding Access for Rare Disease Patients
MALVERN, PA — Endo, a wholly-owned subsidiary of Mallinckrodt plc, has introduced the first and only FDA-approved generic version of Amgen’s RAVICTI® (glycerol phenylbutyrate) oral liquid in the United States, …
Endo Launches First Generic Version of Amgen’s RAVICTI, Expanding Access for Rare Disease Patients Read More